Lenox Wealth Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Lenox Wealth Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,035	Closed	-$8K	–	592
2018 Q1	$8K	Hold	1,035	–	–	﹤0.01%	375
2017 Q4	$10K	Hold	1,035	–	–	﹤0.01%	389
2017 Q3	$12K	Hold	1,035	–	–	﹤0.01%	368
2017 Q2	$17K	Hold	1,035	–	–	0.01%	328
2017 Q1	$15K	Hold	1,035	–	–	0.01%	150
2016 Q4	$14K	Hold	1,035	–	–	0.01%	156
2016 Q3	$19K	Hold	1,035	–	–	0.02%	143
2016 Q2	$15K	Hold	1,035	–	–	0.01%	153
2016 Q1	$12K	Hold	1,035	–	–	0.01%	163
2015 Q4	$14K	Hold	1,035	–	–	0.01%	161
2015 Q3	$11K	Hold	1,035	–	–	0.01%	107
2015 Q2	$8K	Hold	1,035	–	–	0.01%	123
2015 Q1	$7K	Hold	1,035	–	–	﹤0.01%	129
2014 Q4	$6K	Hold	1,035	–	–	﹤0.01%	133
2014 Q3	$10K	Hold	1,035	–	–	0.01%	127
2014 Q2	$12K	Hold	1,035	–	–	0.01%	123
2014 Q1	$13K	Buy	1,035 +478	+86%	+$6.11K	0.01%	137
2013 Q4	$7K	Buy	+557	New	+$8.86K	﹤0.01%	152

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CLM

ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

SGA

Sector Gamma AS Oslo, Norway $461M AUM 33.26% 1-Year Est. Return

Lenox Wealth Management's LXRX Position: Q2 2018 in Review

Lenox Wealth Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2018, closing a stake of 1,035 shares — an estimated $8K sold.

Lenox Wealth Management first reported a position in LXRX in Q4 2013 and held it in 18 quarters. The position peaked at $19K in Q3 2016. 121 funds tracked by Wall St. Rank hold LXRX as of Q2 2018.

Lenox Wealth Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Lenox Wealth Management sold 1,035 Lexicon Pharmaceuticals shares in Q2 2018, an estimated $8K.
Lenox Wealth Management first reported a position in Lexicon Pharmaceuticals in Q4 2013 and held it in 18 quarters.
Lenox Wealth Management's Lexicon Pharmaceuticals position peaked at $19K in Q3 2016.
121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2018.

Based on Lenox Wealth Management's 13F filing for Q2 2018, filed 26 Jul 2018.